We treated ccRCC cell lines stably overexpressing OGDHL with the lysosomal inhibitor chloroquine and the proteasome inhibitor MG132 to determine the specific pathway by which OGDHL affects TFAP2A degradation. The gene discussed is TFAP2A; the disease is nonpapillary renal cell carcinoma.